Affiliation:
1. Institute of Bioprocess Engineering and Pharmaceutical Technology, Department Life Science Engineering, University of Applied Sciences Mittelhessen (THM), 35390 Giessen, Germany
Abstract
Accurate and rapid quantification of (infectious) virus titers is of paramount importance in the manufacture of viral vectors and vaccines. Reliable quantification data allow efficient process development at a laboratory scale and thorough process monitoring in later production. However, current gold standard applications, such as endpoint dilution assays, are cumbersome and do not provide true process analytical monitoring. Accordingly, flow cytometry and quantitative polymerase chain reaction have attracted increasing interest in recent years, offering various advantages for rapid quantification. Here, we compared different approaches for the assessment of infectious viruses, using a model baculovirus. Firstly, infectivity was estimated by the quantification of viral nucleic acids in infected cells, and secondly, different flow cytometric approaches were investigated regarding analysis times and calibration ranges. The flow cytometry technique included a quantification based on post-infection fluorophore expression and labeling of a viral surface protein using fluorescent antibodies. Additionally, the possibility of viral (m)RNA labeling in infected cells was investigated as a proof of concept. The results confirmed that infectivity assessment based on qPCR is not trivial and requires sophisticated method optimization, whereas staining of viral surface proteins is a fast and feasible approach for enveloped viruses. Finally, labeling of viral (m)RNA in infected cells appears to be a promising opportunity but will require further research.
Funder
the framework of the industrial collective research program
Federal Ministry for Economic Affairs and Energy (BMWi) through the AiF
Subject
Virology,Infectious Diseases
Reference51 articles.
1. Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo;Heidbuechel;J. Vis. Exp.,2019
2. Orf virus: A promising new therapeutic agent;Wang;Rev. Med. Virol.,2019
3. Viral vector platforms within the gene therapy landscape;Bulcha;Signal Transduct. Target. Ther.,2021
4. Viral Vectors for Gene Transfer;Chen;Curr. Protoc. Mouse Biol.,2018
5. Oncolytic viruses for cancer immunotherapy;Hemminki;J. Hematol. Oncol.,2020